Carvedilol significantly reduced mortality from cardiovascular causes and Study Rundown: The CAPRICORN trial demonstrated that. London, UK – Results of the CAPRICORN trial confirm the benefit of the beta blocker carvedilol (Coreg® – GlaxoSmithKline) in reducing. Description: The CArvedilol Post-infaRct survIval COntRolled evaluatioN ( CAPRICORN) trial was a randomized, placebo-controlled trial.
|Published (Last):||11 October 2011|
|PDF File Size:||14.62 Mb|
|ePub File Size:||13.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
Am Heart J ; 4: Clin Res Cardiol ;95 2: Early intravenous then oral metoprolol in 45 patients with acute myocardial infarction: A randomised trial of propranolol in patients with acute myocardial infarction, I: Effect of timing, dosage, and infarct location.
Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention — the PASSAT Study. Lopressor Intervention Trial Research Group. Register with this site Forgot your password? Carvedilol versus metoprolol in patients undergoing direct percutaneous coronary interventions for myocardial infarction: Effects of the early administration of enalapril crvedilol mortality in patients with acute myocardial infarction.
Effect on mortality of metoprolol in acute myocardial infarction.
J Am Coll Cardiol ;49 9: Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: Email this article Login required.
The primary endpoint was all-cause mortality or hospital admission for cardiovascular problems. Email the author Login required. Clin Res Cardiol ;95 1: Metoprolol in acute myocardial infarction.
Int J Cardiol ;10 3: Pacing Clin Electrophysiol ;28 Suppl 1: Generally, the patients recruited to these trials were at low risk: Van de Werf F.
S Food and Drug Administration.
A double-blind randomized trial. We investigated the long-term efficacy of carvedilol on morbidity and mortality in patients with left-ventricular dysfunction after acute myocardial infarction treated according to current evidence-based practice. The Lopressor Intervention Trial: Carvedilol increases copperzinc superoxide dismutase activity in patients with acute myocardial infarction.
About the Authors B. Data of the studies comparing influence of metoprolol tartrate and carvedilol on MI pathogenesis are presented. Acta Med Scand ; 3: These beneficial effects are additional to those of evidence-based treatments for acute myocardial infarction including ACE inhibitors.
Eur Heart J ;29 User Username Password Remember me Not a user? Analysis was by intention to treat. Article Tools How to cite item. The beneficial effects of beta-blockers on long-term outcome after acute myocardial infarction were shown before the introduction of thrombolysis and angiotensin-converting-enzyme ACE inhibitors.
Editor in chief Boytsov S. Basic Clin Pharmacol Toxicol ; 2: Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, carvedilpl complications. Rational Pharmacotherapy in Cardiology. Body weight changes with beta-blockers use: Randomised trial of intravenous atenolol among 16 cases of suspected acute myocardial infarction: Effects of carvedilol early after myocardial infarction: After myocardial infarction carvedilol improves insulin resistance compared to metoprolol.
Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. Eur Heart J ;8 Am J Cardiol ;56 JAMA ; Study medication was progressively increased to a maximum of 25 mg twice daily during the next weeks, and patients were followed up until the requisite number of primary endpoints had occurred.
Center for Drug Evaluation and Research, U. This work is licensed under a Creative Commons Attribution 4. Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: Last changes in guidelines regarding beta-blockers prescription to patients with MI are presented. Keywords acute coronary syndrome ambulatory blood pressure monitoring amlodipine apixaban arterial hypertension atherosclerosis atrial fibrillation beta-blockers cardiovascular diseases chronic heart failure hypertension ischemic heart disease lisinopril metabolic syndrome myocardial infarction obesity risk factors rivaroxaban statins stroke warfarin.
J Am Coll Cardiol ;51 2: Keywords myocardial infarction, beta-blocker, carvedilol, metoprolol.
In patients treated long-term after an acute myocardial infarction complicated by left-ventricular systolic dysfunction, carvedilol reduced the frequency of all-cause and cardiovascular mortality, and recurrent, non-fatal myocardial infarctions.